Congenital Hyperinsulinism Treatment Market, by Disease Type, Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other, Route of Administration, Distribution Channel, & Region - Size, Share, Outlook, & Opportunity Analysis, 2022 - 2030

PUBLISHED: November 7, 2022

PAGES: 190 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Congenital hyperinsulinism(CHI) also called as hyperinsulinemic hypoglycemia, a rare endocrine condition that causes low blood glucose levels and occurs mainly in newborn babies, infants and children leading to permanent brain injury and is most frequent cause of severe hypoglycemia. Over secretion of insulin by beta cells in pancreas leads to gene mutation in KATP channel genes (ABCC8 and KCNJ11, HNF4A, HNF1A, HADH, and UCP2 or activating mutations of GLUD1, GCK, and SLC16A1) that cause congenital hyperinsulinism. There is significant risk of permanent brain damage in CHI, hence it is necessary to make a prompt diagnosis and obtain immediate management of the disease to prevent complications such as epilepsy, cerebral palsy and neurodevelopmental deficits. According to the National Organization for Rare Disorders database, approximately 1/25,000 to 1/50,000 HI births occurs in most of the countries including HI develop hypoglycemia during the first month of life. Irritability, sleepiness, excessive hunger, rapid heart rate are common symptoms that occurs while more severe symptoms, such as seizures and coma occur. There are many causes of congential hyperinsulinism based on different forms of the disease for example there are transient forms while some are due to genetic defects and persist for life. Prematurely born babies sometimes, develop hypoglycemia due to excessive insulin secretion. The cause of this inappropriate insulin secretion is still not clear, but it can last a few days to months.

Market Dynamics

Ongoing research for development of novel therapeutic options for the treatment of congenital hyperinsulinismby various key players such as Zealand Pharma A/S, Hanmi Pharm.Co., Ltd., Eli Lilly and Company is anticipated to drive the growth of global congenital hyperinsulinismtreatment market over the forecast period. For instance, in May 2019, Zealand Pharma A/S, a biotechnology company initiated Phase 3 clinical trial of Dasiglucagon. The study aims to assess the efficacy and safety of Dasiglucagon for the treatment of pediatric patients with congenital hyperinsulinism. The study is estimated to be completed by December 2022. Dasiglucagon is a peptide analogue of glucagon consisting 7 amino acid substitutions engineered to eliminate fibril formation as well as peptide aggregation.

Key features of the study:

This report provides an in-depth analysis of the global congenital hyperinsulinism treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global congenital hyperinsulinism treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global congenital hyperinsulinism treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global congenital hyperinsulinism treatment market

Detailed Segmentation:

Global Congenital Hyperinsulinism Treatment Market, By Disease Type:
- KATP-HI
- GDH-HI
- GK-HI
- Other (SCHAD HI, HNF4A/HNF1A, etc.)
Global Congenital Hyperinsulinism Treatment Market, By Drug Type:
- Diazoxide
- Octerotide
- Glucagon
- Nifedipine
- Other (Sirolimus, Chlorothiazide, etc.)
Global Congenital Hyperinsulinism Treatment Market, By Route of Administration:
- Oral
- Parental
Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Congenital Hyperinsulinism Treatment Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Hanmi Pharm.Co., Ltd.,
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Zealand Pharma A/S
- Eli Lilly and Company
- Xeris Pharmaceuticals, Inc.,
- Rezolute, Inc.,
- Fresenius Kabi AG
- Eiger BioPharmaceuticals.,
- Crinetics Pharmaceuticals, Inc.,
- AmideBio,LLC
- Jolly Healthcare
- e5 Pharma,LLC
- Merck & Co., Inc.
- Novo Nordisk A/S
- Amphaster Pharmaceuticals, Inc.
- USV Private Limited
- Teva Pharmaceutical Industries

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI5329

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Congenital Hyperinsulinism Treatment Market, By Disease Type, 2017-2030,(US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
KATP-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
GDH-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
GK-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Other (SCHAD HI, HNF4A/HNF1A HI, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

5. Global Congenital Hyperinsulinism Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Diazoxide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Octreotide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Glucagon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Nifedipine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Other (Sirolimus, Chlorothiazide, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Congenital Hyperinsulinism Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Congenital Hyperinsulinism Treatment Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Zealand Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
Xeris Pharmaceuticals, Inc.
Rezolute, Inc.
Hanmi Pharm.Co., Ltd.
Fresenius Kabi AG
Eiger BioPharmaceuticals.
Crinetics Pharmaceuticals, Inc.
AmideBio,LLC
Jolly Healthcare
e5 Pharma, LLC.
Merck & Co., Inc.
Novo Nordisk A/S
Amphastar Pharmaceuticals.Inc,
USV Private Limited.
Teva Pharmaceutical Industries Ltd.